WO1999001213A1 - Microbilles preparees a partir d'hydrogel de polysaccharide reticule pouvant contenir des molecules d'interet biologique ou des cellules - Google Patents
Microbilles preparees a partir d'hydrogel de polysaccharide reticule pouvant contenir des molecules d'interet biologique ou des cellules Download PDFInfo
- Publication number
- WO1999001213A1 WO1999001213A1 PCT/FR1998/001414 FR9801414W WO9901213A1 WO 1999001213 A1 WO1999001213 A1 WO 1999001213A1 FR 9801414 W FR9801414 W FR 9801414W WO 9901213 A1 WO9901213 A1 WO 9901213A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- encapsulated
- stirring
- capsules
- cells
- dispersion
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/11—Encapsulated compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/70—Fixation, conservation, or encapsulation of flavouring agents
- A23L27/72—Encapsulation
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/25—Silicon; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/27—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/29—Titanium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/678—Tocopherol, i.e. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/732—Starch; Amylose; Amylopectin; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q13/00—Formulations or additives for perfume preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
- B01J13/02—Making microcapsules or microballoons
- B01J13/06—Making microcapsules or microballoons by phase separation
- B01J13/14—Polymerisation; cross-linking
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/41—Particular ingredients further characterized by their size
- A61K2800/412—Microsized, i.e. having sizes between 0.1 and 100 microns
Definitions
- the different nfilff ⁇ technologies all follow the same scheme comprising two stages. The first consists in dispersing the product or the preparation to be encapsulated into fine droplets. The second sees the realization of the encapsulation proper by the solidification of droplets either on the surface or in the mass.
- the dispersion is a »ft ⁇ key to the success of a good encapsulation because it conditions at the same time the effectiveness of encapsula ⁇ on, the size of the balls, the homogeneity of size and the shape.
- Extrusion consists in dispersing the solution to be encapsulated by dropping it drop by drop in a medium where the gelification of the drops or the formation of a surface membrane is carried out (Levy and Poncelet, 1994, Biofutur, Mars, 16-21) .
- the drip is obtained using a needle.
- this technique can be modulated by the application of a coaxial air current of a potential difference or a vibration. If it is thus possible to better control the size range, it It seems impossible to envisage industrial production for capsules smaller than 500 microns at a time for reasons of yields and size dispersion.
- This step leads to the - synthesis of the microcapsule containing the structure to be encapsulated, by the establishment of a membrane of varied nature more or less resistant or by complete solidification forming a solid ball by polymerization or gelation.
- the capsule must be biocompatible, must not modify physiological balances, must not induce side effects, must be biodegradable after having fulfilled its role and above all be stable in its conditions of use. In addition, it must have a high encapsulation capacity and allow effective modulation of the properties of permeability to nutrients, to the compounds produced or encapsulated, as well as to the various compounds or elements of the medium of use or implantation of the capsules. Finally, the encapsulation technique must be easily industrializable.
- the capsule can therefore have the following criteria:
- the compound must be compatible with the stability of the compounds to be encapsulated
- interfacial polymerization To overcome the low chemical stability of the capsules obtained by ionic coating, other techniques have been developed, called interfacial polymerization. All these techniques are based on the same principle.
- An aqueous suspension of proteins or polymers containing the product to be encapsulated is dispersed in an organic phase with which the crosslinking agent is added, generally a polychloride of acid which reacts with the amino groups at the interface, to give a membrane.
- nylon type FR 2 642329A1
- Macroencapsulation on hollow fiber provides very good results in terms of cell survival and in vivo stability (Aebischer et al, 1991, Exp. Neurol., 111, 269).
- these techniques have certain disadvantages such as:
- hydrogels from polymers used in hollow fibers such as acrylonitrile and sodium methaUysulfonate (FR 2696755A1), or ethylene gh / col muttiacrylate photopolymers (WO 9631199), or potyacrylamides.
- polymers used in hollow fibers such as acrylonitrile and sodium methaUysulfonate (FR 2696755A1), or ethylene gh / col muttiacrylate photopolymers (WO 9631199), or potyacrylamides.
- the capsule is biocompatible and does not cause an organism response in the event that it is implanted
- the size is controllable - the porosity can be modulated
- microcapsules according to the invention are characterized in that they consist of a hydrogel prepared by covalent crosslinking of biocompatible polymers preferably chosen from polysaccharides.
- the present invention relates to a new type of microcapsule useful in particular for the transport of compounds for biological use.
- microcapsules have a very important stability, a defined size which can be modulated according to the applications. They are capable of encapsulating various synthetic, semi-synthetic, recombinant or natural molecules, bacterial cells, yeasts, mammalian cells, oily compounds, flavors and powders. These microcapsules can be used to allow or increase solubility and aqueous dispersibility, to provide protection against responses of the immune system during implants, to facilitate the handling and recovery of ferments during vinification and fermentation processes in general.
- microcapsules can also be used to obtain a modulation of the modes of release of the molecules over time, to improve the physicochemical stability over time of sensitive molecules, to protect the encapsulated compounds against mechanical and thermal aggressions, to ensure transport molecules within complex eukaryotic or prokaryotic biological systems intended to ensure chemical, photochemical, enzymatic immunological reactions for pharmaceutical, cosmetological, diagnostic, study and research, fermentation applications.
- the present invention relates to a new type of biocompatible polymer matrix intended for the encapsulation of various compounds and characterized in that the crosslinking phase of the polymer can be modulated to allow the internal incorporation of water-soluble or hydrophobic molecules. This homogeneous encapsulation is introduced after the first step of crosslinking the polymer and before complete gelation.
- the compound to be encapsulated is added while maintaining agitation
- the reaction medium is then dispersed in a hydr ⁇ phobic organic phase until complete polymerization of the capsules
- Microcapsules are thus obtained after washing, allowing re-encapsulation of numerous compounds.
- the reaction medium containing the encapsulation product is not dispersed in the hydrophobic organic phase. It is left to stand until solidified in the form of a gel.
- the microcapsules containing the product to be encapsulated are then obtained by mechanical grinding.
- the microcapsules obtained are not spherical but this technique makes it possible to obtain very small sizes of microcapsules without the use of surfactants.
- this technique allows the incorporation of these cells while maintaining excellent viability and functionality, both for bacterial cells, yeasts and mammalian cells, for example glands adrenal or PC12 dopaminergic lines.
- the present invention relates to a microcapsule characterized in that it comprises in order:
- hydrogel matrix based on carbohydrates or crosslinked polyols, hydrophilic, non-liquid and biocompatible - inclusions of the compounds to be encapsulated which are dispersed throughout the matrix
- the matrix can be prepared by various methods well known to those skilled in the art.
- it is a polysaccharide, preferably biodegradable, linear or branched, for example starch and derivatives, ceUulose, dextran, polysaccharides derived naturally by ionic functions, for example chitosan, hyaluronic acids, alginates, carrageenans, hydrogel or porysaccharide matrix, is obtained by crosslinking, by methods well known to those skilled in the art.
- Crosslinking methods can be carried out by the use of bifunctional agents capable react with the hydroxyl groups of polysaccharides such as epichlorohydrin, epibromohydrin or difunctionals such as bis-epoxides, ctialdehydes, dicarides of dicarboxylic acids, diisothiocyanates, mixed anhydrides of dicarboxylic acids.
- the microcapsules are formed during the last step of the process.
- a first variant of this step consists in mechanically grinding large blocks of matrices obtained by mass polymerization.
- the second consists in resuscitating the matrix in the form of capsules by the technique of polymerization in dispersion in a liquid immiscible with the reaction phase.
- the use of surfactants such as Tween or Span is dependent on the size sought.
- the dispersion in the hydrophobic phase is carried out by stirring in a reactor using a blade or by stirring on a stirring table with circular movement.
- the physico-chemical and mechanical stability as well as the porosity of the microcapsule thus prepared are a function of the crosslinking operating conditions such as the initial dilution of the polymer and / or the amount of crosslinking agent.
- These microcapsules can be used for the administration of molecules by oral, per lingual, nasal, vaginal, rectal, cutaneous, ocular but also pulmonary and parenteral routes. They can also be used for topical applications of keratinous tissues such as dander.
- Hydrophobic compounds such as mineral oils, for example paraffin or silicone, organic oils, for example, olive, calendula, sweet almond, salmon, cod liver, evening primrose, essential oils, flavorings , dyes, mineral powders such as talc, titanium dioxide, zinc oxide, silicates, foundations for insoluble dyes and pigments, oily dispersions of plant extracts, vitamins alone or in oily dispersion , cells for example hepatocytes, streams of Langerhans, pancreatic cells, adrenal meduocells, PC12 dopaminergic cell cells, genetically modified cells, yeasts for example boulardi saccharomyces, saccharomyces cerevisiae, bacteria by example leuconostoc oenos and molecules with therapeutic activity.
- mineral oils for example paraffin or silicone
- organic oils for example, olive, calendula, sweet almond, salmon, cod liver, evening primrose, essential oils, flavorings , dyes, mineral powders such as talc, titanium dioxide, zinc oxide, silicates
- - peptides and their derivatives glucagon, somatostatin, calcitonin, interferon and interleukins, LHRH, rerythropoietin, bradykinin antagonists, polypeptides as well as recombinants from biotechnology
- oligonucleotide analogs and reverse transcriptase inhibitors in particular oligonucleotide analogs and reverse transcriptase inhibitors
- vasodilators diuretics and antidiuretics - prostaglandins
- Example 1 Preparation of microcapsules of silicone hula 400 microns
- Example 2 Preparation of 40 micron vitamin A propionate microcapsules
- Example 3 Preparation of microcapsules of vitamin E / vitamin C / sweet almond oil mixture
- Example 4 Preparation of microcapsules for mixing titanium dioxide powders and magnesium siUcate
- Example 5 Preparation of microcapsules for mixing titanium dioxide and zinc oxide powders
- Example 6 Preparation of microcapsules of rose essential oil of 2000 microns
- the agitation is kept dispersed by slow agitation using an anchor-type blade at a speed between 30 and 50 revolutions / min. After 3 hours of stirring, the capsules are recovered by decantation and then taken up in 16 liters of water and neutralized with 2N HCl. The microcapsules are then washed 3 times by decantation with 8 liters of water. We obtain essential oil capsules of 2000 microns
- Example 7 Preparation of microcapsules of essential oil of rose of 40 microns
- the agitation is kept dispersed by slow agitation using an anchor-type blade at a speed between 30 and 50 revolutions min. After 3 hours of stirring, the capsules are recovered by decantation and then taken up in 16 others of water and neutralized with 2N HCl. The microcapsules are then washed 3 times by decantation with 8 liters of water. 40 micron essential oil capsules are obtained.
- Example 9 Preparation of encapsulated Boulardii saccharomyces yeasts
- Example 10 Preparation of encapsulated Leuconostoc Oenos bacteria
- Example 11 Preparation of large-pore capsules containing leuconostoc oenos
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Birds (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Polymers & Plastics (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Manufacturing Of Micro-Capsules (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP98935081A EP0930937A1 (fr) | 1997-07-03 | 1998-07-02 | Microbilles preparees a partir d'hydrogel de polysaccharide reticule pouvant contenir des molecules d'interet biologique ou des cellules |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR97/08402 | 1997-07-03 | ||
FR9708402A FR2765496B1 (fr) | 1997-07-03 | 1997-07-03 | Microbilles appelees capsules a coeur polymerique capables de transporter des molecules, des principes actifs et/ou des cellules. |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1999001213A1 true WO1999001213A1 (fr) | 1999-01-14 |
WO1999001213A9 WO1999001213A9 (fr) | 1999-04-15 |
Family
ID=9508796
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR1998/001414 WO1999001213A1 (fr) | 1997-07-03 | 1998-07-02 | Microbilles preparees a partir d'hydrogel de polysaccharide reticule pouvant contenir des molecules d'interet biologique ou des cellules |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP0930937A1 (fr) |
FR (1) | FR2765496B1 (fr) |
WO (1) | WO1999001213A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2913884A1 (fr) * | 2007-03-21 | 2008-09-26 | Oralance Pharma Sa | Systeme galenique hydrophobe non ionisable |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2004243536B2 (en) * | 2003-05-28 | 2007-10-11 | Unilever Plc | Satiety enhancing food products |
FR2862980B1 (fr) * | 2003-11-28 | 2006-03-03 | Biopredic Internat | Moyens pour le transport et la conservation de cellules ou tissus vivants |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0246469A1 (fr) * | 1986-05-03 | 1987-11-25 | Hoechst Aktiengesellschaft | Procédé d'encapsulation de substances biologiquement actives |
WO1992021329A1 (fr) * | 1991-06-04 | 1992-12-10 | A Et S Biovecteurs | Vecteur particulaire biodegradable et procede de synthese |
WO1993017784A1 (fr) * | 1992-03-11 | 1993-09-16 | Coletica | Microcapsules a parois en polysaccharides contenant des fonctions alcools primaires, et compositions en contenant |
-
1997
- 1997-07-03 FR FR9708402A patent/FR2765496B1/fr not_active Expired - Fee Related
-
1998
- 1998-07-02 EP EP98935081A patent/EP0930937A1/fr not_active Withdrawn
- 1998-07-02 WO PCT/FR1998/001414 patent/WO1999001213A1/fr not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0246469A1 (fr) * | 1986-05-03 | 1987-11-25 | Hoechst Aktiengesellschaft | Procédé d'encapsulation de substances biologiquement actives |
WO1992021329A1 (fr) * | 1991-06-04 | 1992-12-10 | A Et S Biovecteurs | Vecteur particulaire biodegradable et procede de synthese |
WO1993017784A1 (fr) * | 1992-03-11 | 1993-09-16 | Coletica | Microcapsules a parois en polysaccharides contenant des fonctions alcools primaires, et compositions en contenant |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2913884A1 (fr) * | 2007-03-21 | 2008-09-26 | Oralance Pharma Sa | Systeme galenique hydrophobe non ionisable |
WO2008125423A1 (fr) * | 2007-03-21 | 2008-10-23 | Oralance Pharma | Système galénique hydrophobe non ionisable |
Also Published As
Publication number | Publication date |
---|---|
EP0930937A1 (fr) | 1999-07-28 |
WO1999001213A9 (fr) | 1999-04-15 |
FR2765496B1 (fr) | 1999-09-24 |
FR2765496A1 (fr) | 1999-01-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0630287B1 (fr) | Microcapsules a parois en polysaccharides contenant des fonctions alcools primaires, et compositions en contenant | |
EP0693963B1 (fr) | Utilisation d'une reaction de transacylation entre un polysaccharide esterifie et une polyamine pour former en milieu aqueux une membrane au moins en surface de particules gelifiees, particules ainsi realisees, procedes et compositions en contenant | |
Yao et al. | Microcapsules/microspheres related to chitosan | |
CN1189159C (zh) | 含水溶性美容活性组分水性核的微胶囊及含其的组合物 | |
FR2694894A1 (fr) | Utilisation d'une réaction de transacylation entre un polysaccharide estérifié et une substance polyaminée ou polyhydroxylée pour la fabrication de microparticules, procédé et composition. | |
US6706288B2 (en) | Microparticles | |
US6395302B1 (en) | Method for the preparation of microspheres which contain colloidal systems | |
Baran et al. | Poly (hydroxybutyrate-co-hydroxyvalerate) nanocapsules as enzyme carriers for cancer therapy: an in vitro study | |
AU2001294458B2 (en) | Biodegradable microparticles for controlled release administration, with purified amylopectin-based starch of reduced molecular weight | |
WO1994020078A1 (fr) | Vecteurs particulaires synthetiques et procede de preparation | |
Chen et al. | Preparation and characterization of novel polymeric microcapsules for live cell encapsulation and therapy | |
EP1322411B1 (fr) | Suspension colloidale de particules submicroniques de vectorisation de principes actifs et leur mode de preparation | |
CN108743545A (zh) | 一种海藻酸盐-载药纳米粒-聚阳离子微胶囊及其制备和应用 | |
US20120258047A1 (en) | Epsilon-poly-lysine capsules | |
EP0542969B1 (fr) | Vecteur particulaire biodegradable et procede de synthese | |
FR2699545A1 (fr) | Agent gélifiant résultant de l'association d'un chitosane et d'un alginate d'alkyle ou d'hydroxyalkyle et son utilisation dans la préparation de compositions cosmétiques et pharmaceutiques. | |
CA2266642A1 (fr) | Matrice ionique biodegradable de polarite interne modulable a polymere greffe | |
WO1999001213A1 (fr) | Microbilles preparees a partir d'hydrogel de polysaccharide reticule pouvant contenir des molecules d'interet biologique ou des cellules | |
US20080124780A1 (en) | Hybrid immobilized catalytic system with controlled permeability | |
Strand et al. | Microcapsule formulation and formation | |
AU752746B2 (en) | Sun protection product with microparticles on the basis of water-insoluble linear polyglucan | |
WO2006030111A2 (fr) | Microparticules polymeriques biodegradables | |
CA2157384C (fr) | Vecteurs particulaires synthetiques et procede de preparation | |
Levy et al. | Microcapsules with walls made of cross-linked starch derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998935081 Country of ref document: EP |
|
AK | Designated states |
Kind code of ref document: C2 Designated state(s): CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: C2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
COP | Corrected version of pamphlet |
Free format text: PAGE 1, DESCRIPTION, REPLACED BY A NEW PAGE 1 |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWP | Wipo information: published in national office |
Ref document number: 1998935081 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: CA Ref country code: JP Ref document number: 1999506541 Format of ref document f/p: F |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998935081 Country of ref document: EP |